Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

CORAL SPRINGS, Fla., April 19, 2018 -- via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that they have partnered with NxGen Brands, LLC; a company specializing in the sales and marketing of innovative healthcare products and service solutions, to market and distribute Nyloxin® through their various distribution platforms.

“We are pleased to be working with NxGen Brands to expand the marketing of Nyloxin,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Over the past year, we have brought the Nyloxin product line back under our control and have updated our own websites. These efforts to increase internet awareness will continue as we join other marketing groups to greatly expand our reach to educate consumers about Nyloxin and get the product into the hands of those who need it most,” he continued. “We will also be working with NxGen Brands in our capacity as consultants to aid in expanding their in-house product line, improve their manufacturing and look for other synergies for combined growth,” he concluded.

Nyloxin® is a safe, non-narcotic, and non-addictive Homeopathic pain reliever clinically proven to treat moderate to severe chronic pain while not impairing cognitive function. Nyloxin® offers several benefits as pain relievers and anti-inflammatory agents. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, Nyloxin® offers an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain relieving effects. Nyloxin® has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies.

“NxGen Brands is excited to help educate consumers about the Nyloxin products,” commented Nicholas Brana, President of NxGen Brands. “Our company is actively seeking best-in-class products to represent and distribute. We are also looking forward to working with the knowledgeable staff at Nutra Pharma in improving our other product lines as well as having Nutra Pharma launch additional products through our distribution channels,” he continued. "We will begin offering Nyloxin through our current sales and marketing channels as we expect to build a long-term relationship with Nutra Pharma," he concluded.

About NxGen Brands, LLC
NXGEN provides product sourcing, branding, payment, distribution, and knowledge base through a revolutionary architecture to maintain customer loyalty and capture market share. NxGen Products (NXGEN) is committed to research and to developing a growing portfolio of best-in-class, physician-developed, natural health supplements designed to provide our customers with a better, healthier, and longer life. NXGEN is proud to offer some of the best-known and most highly regarded products on the market. www.leafywell.com

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The agreement with NxGen Brands, LLC should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.